School-based e-Health Non-Communicable Disease (NCD) Prevention Program
Launched by AGA KHAN UNIVERSITY · Nov 4, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new program designed to help high school students in Karachi, Pakistan, learn more about preventing noncommunicable diseases (NCDs), which are health issues like heart disease and diabetes that are not spread from person to person. The program uses a series of lessons delivered by trained facilitators to teach students about important topics such as healthy eating, staying active, and avoiding harmful habits like smoking and excessive drinking. Researchers want to see if this program can effectively improve students' knowledge, attitudes, and practices regarding these health issues compared to students who do not participate.
To take part in this trial, students need to be enrolled in grades 9 to 12 at secondary or higher secondary schools in Karachi. Teachers, parents, and school administrators can also participate in discussions about the program. Participants in the program will attend six interactive sessions, each lasting 30 to 40 minutes, where they will learn about the key risk factors for NCDs. This study is important because it may help shape better health education for young people, ultimately leading to healthier lifestyles.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Phase 1 (FGDs and Interviews)
- • Students currently enrolled in secondary and higher secondary schools in Karachi and are in grades 9 to 12.
- • Teachers who have been employed in secondary and higher secondary schools in Karachi for a minimum duration of 6 months.
- • Parents or legal guardians of students who are currently enrolled in secondary and higher secondary schools in Karachi.
- • Principals and vice principals of secondary and higher secondary schools in Karachi, District Education Officers, and decision-makers at Provincial Department of Education.
- • Phase 2 (Intervention)
- • - Both study and control group would be selected from secondary schools (students in grades 9-10) and Higher Secondary Schools (students in grades 11-12) located in Karachi, Pakistan
- • Phase 3 (FGDs) - Participants from grades 9 to 12 of the secondary and higher secondary schools who actively participated in the intervention and attended all the health-promoting sessions (equal representation of male and female)
- Exclusion Criteria:
- • - Schools outside Karachi
About Aga Khan University
Aga Khan University (AKU) is a distinguished institution dedicated to improving health and education across developing regions. Established in 1983, AKU is recognized for its commitment to research excellence, particularly in clinical trials that address pressing health issues in diverse populations. With a focus on advancing medical knowledge and practice, AKU's clinical trial initiatives are designed to foster innovative solutions and enhance patient care. The university collaborates with various local and international partners, leveraging its multidisciplinary expertise to conduct rigorous research that informs public health policy and improves health outcomes in communities served by its facilities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Karachi, Sindh, Pakistan
Karachi, Sindh, Pakistan
Karachi, Sindh, Pakistan
Karachi, Sindh, Pakistan
Karachi, Sindh, Pakistan
Karachi, Sindh, Pakistan
Karachi, Sindh, Pakistan
Patients applied
Trial Officials
Dr. Tazeen Saeed Ali, Ph.D
Principal Investigator
Aga Khan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported